Bio-Techne (Nasdaq:TECH) - Aandelenkoers, Nieuws & Analyse

TECH Overzicht aandelen

Bio-Techne Corporation, samen met haar dochterondernemingen, ontwikkelt, produceert en verkoopt life science reagentia, instrumenten en diensten voor de onderzoeks-, diagnostiek- en bioprocessingmarkten wereldwijd.

Over het bedrijf

TECH fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	3/6
Prestaties in het verleden	2/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 63.1% onder onze schatting van de reële waarde

De winst zal naar verwachting met 21.23% per jaar groeien

Risicoanalyse

Winstmarges (12.9%) zijn lager dan vorig jaar (21.6%)

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Biotech Innovation And Acquisition Propel Revenue Growth Amid Industry Challenges

Key Takeaways Stabilizing biopharma markets and innovative product launches are driving revenue growth, particularly in cell and gene therapy. Cost containment and strategic acquisitions are enhancing operating margins and market positioning, supporting future investments and expansion.

View narrative

US$83.17

6.7% undervalued

8.27%

Revenue growth p.a.

7 days ago

Bio-Techne Corporation Concurrenten

Charles River Laboratories International

NYSE:CRL

US$9.4b

Bruker

NasdaqGS:BRKR

US$9.0b

Avantor

NYSE:AVTR

US$15.3b

Qiagen

NYSE:QGEN

US$9.7b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Bio-Techne
Historische aandelenkoersen
Huidige aandelenkoers	US$77.62
52 Week Hoogtepunt	US$85.57
52 Week Laag	US$55.63
Bèta	1.27
11 maand verandering	3.80%
3 maanden verandering	9.39%
1 Jaar Verandering	30.19%
33 jaar verandering	-38.17%
5 jaar verandering	52.23%
Verandering sinds IPO	12,016.29%

Recent nieuws en updates

Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Sep 26

Recent updates

Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

May 21

These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Apr 30

Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Apr 15

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

Apr 04

We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Jan 17

Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Dec 30

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Dec 05

Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Oct 10

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Sep 22

A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Sep 01

At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Jul 10

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Jun 22

With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Jun 07

Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

May 23

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Apr 05

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Mar 21

Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

Mar 06

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Jan 03

We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Dec 15

Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Nov 30

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Nov 17

Bio-Techne releases new AVV viral titer assays

Oct 11

At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Sep 26

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Sep 12

Bio-Techne to seek shareholder approval for 4- for-1 stock split

Sep 01

Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Aug 29

Bio-Techne releases Quantist Luminex data analysis software

Aug 18

Rendement voor aandeelhouders

	TECH	US Life Sciences	US Markt
7D	9.7%	3.7%	-0.8%
1Y	30.2%	18.9%	31.5%

Rendement versus industrie: TECH overtrof de US Life Sciences industrie, die het afgelopen jaar een rendement 18.9 % opleverde.

Rendement versus markt: TECH kwam overeen met de US markt, die het afgelopen jaar een rendement opleverde van 31.5 %.

Prijsvolatiliteit

Is TECH's price volatile compared to industry and market?
TECH volatility
TECH Average Weekly Movement	5.5%
Life Sciences Industry Average Movement	7.7%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	2.8%

Stabiele aandelenkoers: TECH heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van TECH is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1976	3,100	Kim Kelderman	www.bio-techne.com

Bio-Techne Corporation, samen met haar dochterondernemingen, ontwikkelt, produceert en verkoopt life science reagentia, instrumenten en diensten voor onderzoek, diagnostiek en bioprocessing markten wereldwijd. Het bedrijf is actief in twee segmenten, Protein Sciences en Diagnostics and Genomics. Het segment Protein Sciences ontwikkelt en produceert biologische reagentia die worden gebruikt in verschillende aspecten van biowetenschappelijk onderzoek, diagnostiek en cel- en gentherapie, zoals cytokinen en groeifactoren, antilichamen, kleine moleculen, weefselkweeksera en celselectietechnologieën.

Bio-Techne Corporation Samenvatting

Hoe verhouden de winst en inkomsten van Bio-Techne zich tot de beurswaarde?
TECH fundamentele statistieken
Marktkapitalisatie	US$12.04b
Inkomsten(TTM)	US$150.68m
Inkomsten(TTM)	US$1.17b

81.7x

Koers/Winstverhouding

10.5x

P/S-verhouding

Is TECH overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TECH resultatenrekening (TTM)
Inkomsten	US$1.17b
Kosten van inkomsten	US$403.30m
Brutowinst	US$768.29m
Overige uitgaven	US$617.61m
Inkomsten	US$150.68m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.95
Brutomarge	65.58%
Nettowinstmarge	12.86%
Schuld/Eigen Vermogen Verhouding	14.0%

Hoe presteerde TECH op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.4%

Huidig dividendrendement

34%

Uitbetalingsratio

Betaalt TECH een betrouwbaar dividend?

Zie TECH dividendgeschiedenis en benchmarks

Wanneer moet je TECH kopen om een aanstaand dividend te ontvangen?
Bio-Techne dividenddata
Ex Dividend Datum	Nov 08 2024
Betaaldatum dividend	Nov 22 2024
Dagen tot Ex-dividend	2 days
Dagen tot dividendbetaaldatum	16 days

Betaalt TECH een betrouwbaar dividend?

Zie TECH dividendgeschiedenis en benchmarks

TECH Overzicht aandelen

Beloningen

Risicoanalyse

Biotech Innovation And Acquisition Propel Revenue Growth Amid Industry Challenges

Bio-Techne Corporation Concurrenten

NYSE:CRL

US$9.4b

NasdaqGS:BRKR

US$9.0b

NYSE:AVTR

US$15.3b

NYSE:QGEN

US$9.7b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Bio-Techne Corporation Announces the Release of Clinically Relevant Spatial Biology Data

First quarter dividend of US$0.08 announced

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2024, Payable on November 22, 2024

Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

ScaleReady and Bio-Techne Corporation Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies

Recent updates

Bio-Techne Corporation Announces the Release of Clinically Relevant Spatial Biology Data

First quarter dividend of US$0.08 announced

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2024, Payable on November 22, 2024

Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

ScaleReady and Bio-Techne Corporation Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies

Bio-Techne Corporation, Annual General Meeting, Oct 24, 2024

Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching

Full year 2024 earnings: EPS misses analyst expectations

Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings

Consensus EPS estimates fall by 14%

Fourth quarter dividend of US$0.08 announced

Full year 2024 earnings: EPS misses analyst expectations

Executive VP of Finance & CFO exercised options and sold US$1.8m worth of stock

Bio-Techne Corporation Declares Dividend for the Quarter Ended June 30, 2024, Payable on August 30, 2024

Bio-Techne Corporation Announces the Launch of the Leo™ System

Executive VP of Finance & CFO exercised options and sold US$1.1m worth of stock

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne Corporation to Showcase Multiple Applications of the MauriceFlex™? System at the Annual ASMS Conference

Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration

Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

Third quarter dividend of US$0.08 announced

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2024, Payable on May 24, 2024

Bio-Techne Corporation Appoints Dr. Judith Klimovsky to Board of Directors

These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay

Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

Independent Director recently sold US$801k worth of stock

Consensus EPS estimates fall by 17%

Second quarter dividend of US$0.08 announced

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended December 31, 2023, Payable February 26, 2024

Bio-Techne Corporation Sets New Standard with the Development of A Next-Generation, Protease-Free RNAscope Spatial Multiomics Workflow

Bio-Techne Corporation to Report Q2, 2024 Results on Feb 01, 2024

We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Bio-Techne Corporation Appoints Matthew F. Mcmanus as President, Diagnostics and Genomics Segment, Effective January 8, 2024

Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Executive VP of Finance & CFO exercised options and sold US$1.5m worth of stock

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

New minor risk - Earnings quality

Price target decreased by 19% to US$81.33

Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended September 30, 2023, Will Be Payable November 24, 2023

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Bio-Techne Corporation to Present New Data Using Lunaphore's Comet Technology at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Bio-Techne Corporation Announces Executive Changes

Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne Corporation Launches the New Maurice Chromeleon Driver Kit, Which Enables Control of its Maurice™ Instrument with the Thermo Scientific™ Chromeleon™ Chromatography Data System

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Bio-Techne Corporation, Annual General Meeting, Oct 26, 2023

A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

New minor risk - Earnings quality

Consensus EPS estimates fall by 17%

Full year 2023 earnings: EPS exceeds analyst expectations

Bio-Techne Corporation (NasdaqGS:TECH) acquired Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others.

At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA.